Maharashtra FDA cancels Cipla warehouse licences
In short
Maharashtra’s FDA cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences’ Pune warehouse. The action was linked to concerns about Reactin Plus packaging, storage and record-keeping.
This matters because it affects a Cipla warehouse and its operations. Cipla says the facility follows the required protocols, but the next step is not stated.
What the reporting says
Maharashtra FDA cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences' Pune warehouse over findings linked to Reactin Plus packaging, storage and record-keeping. Cipla said the decision was disappointing and that the facility follows required protocols, but the available reporting does not state whether the action will be challenged or reversed. The immediate effect is a licence loss for the warehouse.
Why it matters
Maharashtra FDA cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences' Pune warehouse after findings tied to Reactin Plus packaging, storage and record-keeping. Cipla called the decision disappointing and said the facility complies with required protocols. The reporting does not state whether the licences will be restored or whether the company will appeal.